IDH1 and cancer: Future experiments may seek to test whether altered α-ketoglutarate or 2HG concentrations can affect HIF-1a or TET2 pathway members in vitro, and identify the cellular pathways necessary for the IDH mutants to exert a cancer-related phenotype.